FrancophonIA/ELRC3.0 huggingface dataset:
English: If the patient is considered to need parenteral benzodiazepine treatment, this should not be given until at least one hour after IM olanzapine administration.
Croatian: Ako se ocijeni da je bolesniku potrebno parenteralno liječenje benzodiazepinom, ono se ne smije primijeniti najmanje jedan sat nakon primjene intramuskularnog olanzapina.
English: Your doctor will change your treatment to ZYPREXA tablets, as soon as appropriate.
Croatian: Vaš će liječnik liječenje ZYPREXA injekcijama zamijeniti liječenjem ZYPREXA tabletama čim to bude primjereno.
English: No other solutions should be used for reconstitution (see section
Croatian: Za rekonstituciju se ne smiju se upotrebljavati druge otopine (vidjeti dio 6.2).
English: Treatment with ZYPREXA powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.
Croatian: Liječenje ZYPREXA praškom za otopinu za injekciju treba prekinuti i započeti primjenu oralnog olanzapina čim to bude klinički primjereno.
English: Not more than 3 injections should be given in any 24 hour period and the maximum daily dose of 20 mg (including all formulations) of olanzapine should not be exceeded.
Croatian: Ne smiju se dati više od tri injekcije unutar razdoblja od 24 sata i ne smije se prekoračiti maksimalna dnevna doza od 20 mg olanzapina (uključujući sve formulacije).
English: Discard syringe and unused solution appropriately
Croatian: Štrcaljku i neiskorištenu otopinu odgovarajuće zbrinite.
English: The safety and efficacy of IM olanzapine has not been evaluated in patients with alcohol or drug intoxication (either with prescribed or illicit drugs) (see section 4.5).
Croatian: Sigurnost i djelotvornost intramuskularnog olanzapina nisu ocijenjene u bolesnika intoksiciranih alkoholom, (propisanim) lijekovima ili ilegalnim drogama (vidjeti dio 4.5).
English: Potential for olanzapine to affect other medicinal products Olanzapine may antagonise the effects of direct and indirect dopamine agonists (see section 6.2).
Croatian: Mogući utjecaj olanzapina na druge lijekove Olanzapin može antagonistički djelovati na učinke izravnih i neizravnih agonista dopamina (vidjeti dio 6.2).
English: When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the dose.
Croatian: Ako je prisutno više čimbenika koji mogu usporiti metabolizam (ženski spol, starija životna dob, nepušač), potrebno je razmotriti smanjenje doze.
English: Patients treated with any antipsychotic medicines, including ZYPREXA, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Croatian: U bolesnika liječenih bilo kojim antipsihotikom, uključujući lijek ZYPREXA, potrebno je redovito pratiti razinu lipida prema smjernicama za primjenu antipsihotika, na primjer, na početku liječenja, 12 tjedana nakon početka liječenja olanzapinom te svakih 5 godina nakon toga.
English: • The other ingredients are lactose monohydrate, tartaric acid, hydrochloric acid and sodium hydroxide.
Croatian: • Drugi sastojci su laktoza hidrat, tartaratna kiselina, kloridna kiselina i natrijev hidroksid.
English: Parenteral medicines should be inspected visually for particulate matter prior to administration.
Croatian: Parenteralne lijekove treba prije primjene vizualno pregledati kako bi se utvrdilo sadrže li čestice.
English: Patients who have taken more ZYPREXA than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Croatian: Bolesnici koji su uzeli više lijeka ZYPREXA nego što su trebali imaju sljedeće simptome: ubrzan rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
English: 44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
Croatian: 44 bolesnika sa shizofrenijom u dobi iznad 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim posebnim profilom nuspojava.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 27 September 1996
Croatian: Datum prvog odobrenja: 27. rujna 1996.
English: Hepatitis (including hepatocellular, cholestatic or mixed liver injury) 11
Croatian: (uključujući hepatocelularno, kolestatsko ili mješovito oštećenje jetre)11
English: Patients should remain recumbent if dizzy or drowsy after injection until examination indicates that they are not experiencing hypotension including postural hypotension, bradyarrhythmia and/or hypoventilation.
Croatian: Ako osjete omaglicu ili omamljenost nakon injekcije, bolesnici moraju ostati u ležećem položaju sve dok se pregledom ne isključi hipotenzija, uključujući posturalnu hipotenziju, bradiaritmiju i/ili hipoventilaciju.
English: • The other ingredients are - (tablet core) lactose monohydrate, hyprolose, crospovidone, microcrystalline cellulose, magnesium stearate and - (tablet coating) hypromellose, titanium dioxide (E171), carnauba wax.
Croatian: • Drugi sastojci su - (jezgra tablete) laktoza hidrat, hiproloza, krospovidon, mikrokristalična celuloza, magnezijev stearat i - (ovojnica tablete) hipromeloza, titanijev dioksid (E171), karnauba vosak.
English: ZYPREXA powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
Croatian: ZYPREXA prašak za otopinu za injekciju indiciran je za brzu kontrolu agitacije i poremećaja ponašanja u bolesnika sa shizofrenijom ili epizodom manije kada peroralno liječenje nije prikladno.
English: • If you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati lijek ZYPREXA • Ako ste alergični (preosjetljivi) na olanzapin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: New born infant exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Croatian: U novorođenčadi izloženoj antipsihoticima (uključujući olanzapin) tijekom trećeg tromjesečja trudnoće postoji rizik od nastanka nuspojava, uključujući ekstrapiramidne simptome i/ili simptome ustezanja koji nakon poroda mogu varirati po težini i trajanju.
English: ZYPREXA should be stored in its original pack in order to protect from light and moisture.
Croatian: Lijek ZYPREXA treba čuvati u originalnom pakiranju radi zaštite od svjetlosti i vlage.
English: Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo models.
Croatian: Olanzapin je in vitro pokazao veći afinitet za serotoninske 5HT2 nego za dopaminske D2 receptore te veće djelovanje na 5HT2 nego D2 u in vivo modelima.
English: Other very common side effects (may affect more than 1 in 10 people) include weight gain; and increases in levels of prolactin in the blood.
Croatian: Druge vrlo česte nuspojave (mogu se pojaviti u više od 1 na 10 osoba) uključuju povećanje tjelesne težine i povišene razine prolaktina u krvi.
English: EXP Use solution within 1 hour
Croatian: Otopinu upotrijebiti unutar 1 sata.
English: In post marketing reports, temporal association of treatment with IM olanzapine with cases of respiratory depression, hypotension or bradycardia and death have been very rarely reported, mostly in patients who concomitantly received benzodiazepines, and/or other antipsychotic medicinal products or who were treated in excess of olanzapine recommended daily doses (see sections 4.4 and 4.5).
Croatian: U izvješćima nakon stavljanja lijeka u promet vrlo je rijetko prijavljena vremenska povezanost liječenja intramuskularnim olanzapinom sa slučajevima respiratorne depresije, hipotenzije ili bradikardije i smrti, i to uglavnom u bolesnika koji su istodobno primali benzodiazepine i/ili druge antipsihotike ili koji su liječeni većim dozama olanzapina od preporučenih dnevnih doza (vidjeti dijelove 4.4 i 4.5).
English: The efficacy of IM olanzapine has not been established in patients with agitation and disturbed behaviours related to conditions other than schizophrenia or manic episode.
Croatian: Djelotvornost intramuskularnog olanzapina nije utvrđena u bolesnika s agitacijom i poremećajima ponašanja povezanim s drugim stanjima osim shizofrenije ili epizode manije.
English: Dementia-related psychosis and/or behavioural disturbances Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Croatian: Primjena olanzapina se ne preporučuje u bolesnika s psihozom i/ili poremećajima ponašanja uzrokovanima demencijom zbog porasta mortaliteta i rizika od pojave cerebrovaskularnog događaja.
English: Concomitant use of benzodiazepines and other medicinal products Special caution is necessary in patients who have received treatment with other medicinal products having haemodynamic properties similar to those of intramuscular olanzapine including other antipsychotics (oral and/or intramuscular) and benzodiazepines (see section 4.5).
Croatian: Treba biti posebno oprezan u bolesnika liječenih drugim lijekovima koji imaju hemodinamička svojstva slična onima intramuskularnog olanzapina, uključujući druge antipsihotike (oralne i/ili intramuskularne) i benzodiazepine (vidjeti dio 4.5).
English: With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3 % gained ≥ 15 % and 29.1 % gained ≥ 25 % of their baseline body weight.
Croatian: Tijekom dugotrajne izloženosti (najmanje 24 tjedna), u 89,4% bolesnika povećala se tjelesna težina za ≥ 7%, u 55,3% za ≥ 15%, a u 29,1% bolesnika tjelesna težina se povećala za ≥ 25% od njihove tjelesne težine na početku liječenja.
English: 13Undesirable effects listed and observed following administration of oral and LAIM olanzapine, which may also occur following administration of RAIM olanzapine.
Croatian: 13 Neželjeni učinci navedeni su i opaženi nakon primjene oralnog i dugodjelujućeg i.m. olanzapina, a mogu se pojaviti i nakon primjene brzodjelujućeg i.m. olanzapina.
English: Very common symptoms in overdose (> 10 % incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Croatian: Vrlo česti simptomi predoziranja (incidencija >10%) uključuju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidne simptome i smanjenu razinu svijesti u rasponu od sedacije do kome.
English: • If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting
Croatian: • napadaji • ako znate da možda imate nedovoljno soli u organizmu kao posljedicu dugotrajnog teškog proljeva i povraćanja ili zbog uzimanja diuretika (tableta za izlučivanje vode iz organizma)
English: Common (≥ 1/100 to < 1/10): Postural hypotension, hypotension.
Croatian: Često (≥ 1/100 i < 1/10): posturalna hipotenzija, hipotenzija
English: • If you have had a recent heart attack, or have heart disease, including sick sinus syndrome,
Croatian: • poremećaji krvi • ako ste nedavno pretrpjeli srčani udar ili bolujete od srčane bolesti, uključujući sindrom bolesnog sinusa i nestabilnu anginu, ili ako imate nizak krvni tlak
English: All olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors.
Croatian: Svi bolesnici liječeni olanzapinom i bolesnici koji su primali placebo, a u kojih se javio cerebrovaskularni događaj, prethodno su imali čimbenike rizika.
English: In placebocontrolled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementiarelated psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % vs. 1.5 %, respectively).
Croatian: U placebom kontroliranim kliničkim ispitivanjima (trajanja od 6 do 12 tjedana) starijih bolesnika (srednja vrijednost dobi 78 godina) s psihozom i/ili poremećajima ponašanja uzrokovanih demencijom zabilježeno je dvostruko povećanje incidencije smrtnosti u bolesnika liječenih olanzapinom u usporedbi s bolesnicima koji su primali placebo (3,5% naspram 1,5%).
English: It is extremely important that patients receiving intramuscular olanzapine should be closely observed for hypotension including postural hypotension, bradyarrhythmia and/or hypoventilation, particularly for the first 4 hours following injection and close observation should be continued after this period if clinically indicated.
Croatian: Iznimno je važno pomno nadzirati bolesnike koji primaju intramuskularni olanzapin zbog moguće pojave hipotenzije, uključujući posturalnu hipotenziju, bradiaritmiju i/ili hipoventilaciju, naročito tijekom prva 4 sata nakon injekcije.
English: • The use of ZYPREXA in elderly patients with dementia (confusion and memory loss) is not recommended as it may have serious side effects.
Croatian: • Primjena lijeka ZYPREXA u starijih bolesnika s demencijom (smetenošću i zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
English: Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ( ≥ 0.01 % and < 0.1 %) when olanzapine is stopped abruptly.
Croatian: Prekid liječenja Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i < 0,1%) nakon naglog prekida uzimanja olanzapina.
English: Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1 % and < 1 %).
Croatian: Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) prijavljivana je manje često (< 0,01% i < 1%).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 10 mg olanzapine.
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Jedna bočica sadrži 10 mg olanzapina.
English: Each vial contains 10 mg of the active substance.
Croatian: Jedna bočica sadrži 10 mg djelatne tvari.
English: Uncommon (≥ 1/1,000 to < 1/100): Hypoventilation.
Croatian: Manje često (≥ 1/1000 i < 1/100): hipoventilacija
English: Additional pharmacokinetic data following administration of oral olanzapine are described below.
Croatian: Dodatni farmakokinetički podaci o olanzapinu primijenjenom peroralno opisani su u nastavku.
English: What you need to know before you take ZYPREXA
Croatian: Što morate znati prije nego počnete uzimati lijek ZYPREXA
English: Very common: Weight gain13, elevated triglyceride levels14, increased appetite.
Croatian: Poremećaji metabolizma i prehrane Vrlo često: povećanje tjelesne težine13, povišene razine triglicerida14, povećan apetit.
English: If this happens after you have been given ZYPREXA, talk to your doctor.
Croatian: Ako Vam se ovo pojavi nakon uzimanja lijeka ZYPREXA, obratite se svom liječniku.
English: During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Croatian: Tijekom liječenja olanzapinom u kombinaciji s litijem ili divalproeksom, porast tjelesne težine ≥ 7% od početne pojavio se u 17,4% bolesnika tijekom akutnog liječenja (do 6 tjedana).
English: For the same dose of olanzapine administered intramuscularly and orally, the associated area under the curve, half-life, clearance and volume of distribution are similar.
Croatian: Kod primjene jednake doze intramuskularnog i oralnog olanzapina pripadajuće vrijednosti površine ispod krivulje, poluvijeka, klirensa te volumena distribucije su slične.
English: Adults Olanzapine is indicated for the treatment of schizophrenia.
Croatian: Olanzapin je indiciran za liječenje shizofrenije.
English: However, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.
Croatian: Međutim, oprez je potreban prilikom propisivanja olanzapina s lijekovima za koje se zna da produljuju QTc-interval, osobito u starijih osoba, u bolesnika s urođenim sindromom dugog QT-intervala, kongestivnim zatajenjem srca, hipertrofijom srca, hipokalijemijom ili hipomagnezijemijom.
English: Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥ 7 % from baseline body weight in 39.9 % of patients.
Croatian: Dugotrajno liječenje olanzapinom (do 12 mjeseci) radi prevencije relapsa u bolesnika s bipolarnim poremećajem bilo je povezano s povećanjem tjelesne težine ≥ 7% od početne tjelesne težine u 39,9% bolesnika.
English: In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychoticand risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Croatian: Single Photon Emission Computed Tomography) u bolesnika sa shizofrenijom otkrilo je da bolesnici koji reagiraju na olanzapin imaju manju zauzetost strijatalnih D2 receptora od bolesnika koji su reagirali na neke druge antipsihotike i risperidon, dok je zauzetost bila usporediva s onom u bolesnika koji su reagirali na klozapin.
English: A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA
English: • The use of ZYPREXA in elderly patients with dementia is not recommended as it may have serious side effects.
Croatian: • Primjena lijeka ZYPREXA u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
English: • unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;
Croatian: Odmah obavijestite svog liječnika ako imate: • neuobičajene pokrete (česta nuspojava koja se može pojaviti u do 1 na 10 osoba) uglavnom na licu ili jeziku;
English: Clinical signs included sedation, ataxia, tremors, increased heart rate, laboured respiration, miosis, and anorexia.
Croatian: Klinički znakovi uključivali su sedaciju, ataksiju, tremore, ubrzan srčani ritam, otežano disanje, miozu i anoreksiju.
English: (tablet coating) shellac, macrogol, propylene glycol, polysorbate 80 and indigo carmine colour (E132), ethanol anhydrous, isopropyl alcohol, butyl alcohol, ammonium hydroxide
Croatian: (ovojnica tablete) šelak, makrogol, propilenglikol, polisorbat 80 i boja indigo karmin (E132), bezvodni etanol, izopropilni alkohol, butilni alkohol, amonijev hidroksid
English: Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment.
Croatian: Često su uočeni prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza, ALT i AST, osobito u ranoj fazi liječenja.
English: A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.
Croatian: Smanjenje doze olanzapina treba razmotriti u slučaju da se započinje liječenje inhibitorom
English: While olanzapine demonstrated anticholinergic activity in vitro, experience during oral clinical trials revealed a low incidence of related events.
Croatian: Dok olanzapin in vitro pokazuje antikolinergičko djelovanje, iskustvo tijekom kliničkih ispitivanja peroralne primjene otkrilo je nisku incidenciju povezanih događaja.
English: Warnings and precautions Talk to your doctor or nurse before you are given ZYPREXA Injection
Croatian: Obratite se svom liječniku ili medicinskoj sestri prije nego primite ZYPREXA injekciju.
English: In addition, the following side effects have been seen after patients have taken ZYPREXA orally.
Croatian: Osim toga, sljedeće su nuspojave primijećene u bolesnika koji su uzimali oralni oblik lijeka
English: ZYPREXA Injection is for intramuscular use.
Croatian: ZYPREXA injekcija namijenjena je za primjenu u mišić.
English: In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT2A than dopamine D2 receptor occupancy.
Croatian: U ispitivanju pozitronskom emisijskom tomografijom (PET), jedna peroralna doza (10 mg) olanzapina u zdravih dobrovoljaca dovela je do većeg zauzimanja 5HT2A nego dopaminskog D2 receptora.
English: After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender.
Croatian: Nakon peroralne primjene, srednje terminalno poluvrijeme eliminacije olanzapina u zdravih ispitanika variralo je ovisno o dobi i spolu.
English: Discard any unused contents.
Croatian: Zbrinite sav neiskorišten sadržaj.
English: ZYPREXA 2.5 mg, 5 mg, 7.5 mg and 10 mg tablets
Croatian: ZYPREXA 2,5 mg, 5 mg, 7,5 mg i 10 mg tablete
English: Bradycardia QTc prolongation (see section 4.4)
Croatian: QTc interval (vidjeti dio 4.4).
English: There is a risk of feeling drowsy when you are given ZYPREXA.
Croatian: Kad uzimate lijek ZYPREXA postoji rizik da se osjećate omamljeno.
English: IM olanzapine has not been studied in patients with alcohol or drug intoxication (see section 4.4).
Croatian: Intramuskularni olanzapin nije ispitan u bolesnika intoksiciranih alkoholom ili drogom (vidjeti dio 4.4).
English: ZYPREXA Powder for Solution for Injection must not be combined in the syringe with any commercially available medicinal products because of incompatibilities.
Croatian: ZYPREXA prašak za otopinu za injekciju se zbog inkompatibilnosti ne smije miješati u štrcaljki ni s jednim lijekom dostupnim na tržištu.
English: ZYPREXA 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg coated tablets 3 years.
Croatian: ZYPREXA 5 mg, 7,5 mg, 10 mg, 15 mg i 20 mg obložene tablete 3 godine.
English: If you forget to take ZYPREXA Take your tablets as soon as you remember.
Croatian: Uzmite tablete čim se sjetite.
English: Single use vial.
Croatian: Bočica za jednokratnu primjenu.
English: In
Croatian: U
English: Olanzapine for injection should not be combined in a syringe with haloperidol injection because the resulting low pH has been shown to degrade olanzapine over time.
Croatian: Olanzapin za injekciju ne smije se miješati u štrcaljki s haloperidolom za injekcije jer dolazi do snižavanja pH vrijednosti koja s vremenom razgrađuje olanzapin.
English: Each ZYPREXA tablet contains either 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg of the active substance.
Croatian: Jedna ZYPREXA tableta sadrži 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg ili 20 mg djelatne tvari.
English: The vial contains 11.0 mg olanzapine as a solution of 5 mg/ml.
Croatian: 11,0 mg olanzapina u obliku otopine od 5 mg/ml.
English: Common ( ≥ 1/100 to < 1/10): Bradycardia with or without hypotension or syncope, tachycardia.
Croatian: Često ( ≥ 1/100 i < 1/10): bradikardija sa ili bez hipotenzije ili sinkope, tahikardija Manje često (≥ 1/1000 i < 1/100): sinusna pauza
English: Following short term treatment (median duration 47 days), weight gain ≥ 7% of baseline body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %).
Croatian: Nakon kratkotrajnog liječenja (medijan trajanja 47 dana) povećanje tjelesne težine ≥ 7% od početne tjelesne težine bilo je vrlo često (22,2%), povećanje ≥ 15% bilo je često (4,2%), a ≥ 25% bilo je manje često (0,8%).
English: Lorazepam injection should not be used to reconstitute olanzapine for injection as this combination results in a delayed reconstitution time.
Croatian: Za rekonstituciju olanzapina za injekciju ne smije se upotrebljavati lorazepam za injekciju jer njihova kombinacija produljuje vrijeme rekonstitucije.